Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1 Terminated
67 enrolled
GVAX Plus Checkpoint Blockade in Neuroblastoma
Phase 1 Terminated
19 enrolled
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Phase 1 Terminated
6 enrolled
PRIMO
Phase 1 Terminated
25 enrolled
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Phase 1 Terminated
11 enrolled
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Phase 1 Terminated
1 enrolled
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Phase 1 Terminated
9 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Phase 1 Terminated
22 enrolled 14 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Phase 1 Terminated
2 enrolled 14 charts
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Phase 1 Terminated
6 enrolled
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase 1 Terminated
6 enrolled
CheckMate 76U
Phase 1 Terminated
21 enrolled
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Phase 1 Terminated
8 enrolled 16 charts
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
Phase 1 Terminated
5 enrolled 12 charts
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Phase 1 Terminated
82 enrolled
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
15 enrolled
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Phase 1 Terminated
47 enrolled
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Phase 1 Terminated
3 enrolled
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
Phase 1 Terminated
14 enrolled
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Phase 1 Terminated
6 enrolled
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Phase 1 Terminated
22 enrolled
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Phase 1 Terminated
3 enrolled
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Phase 1 Terminated
11 enrolled
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
Phase 1 Terminated
26 enrolled
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Phase 1 Terminated
19 enrolled
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
Phase 1 Terminated
3 enrolled
SRS (Stereotactic Radiosurgery) Plus Ipilimumab
Phase 1 Terminated
4 enrolled
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Phase 1 Terminated
18 enrolled 9 charts
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Phase 1 Terminated
28 enrolled